Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1956 Apr;35(4):374–385. doi: 10.1172/JCI103288

EFFECT OF A PHENYLBUTAZONE ANALOG (4-[PHENYLTHIOETHYL]-1,2-DIPHENYL 3,5-PYRAZOLIDINEDIONE) ON URATE CLEARANCE AND OTHER DISCRETE RENAL FUNCTIONS IN GOUTY SUBJECTS. EVALUATION AS URICOSURIC AGENT 1

T F Yü 1,2,3, Bruce C Paton 1,2,3, Theodore Chenkin 1,2,3, J J Burns 1,2,3, Bernard B Brodie 1,2,3, Alexander B Gutman 1,2,3
PMCID: PMC438822  PMID: 13306779

Full text

PDF
374

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRODIE B. B., YU T. F., BURNS J. J., CHENKIN T., PATON B. C., STEELE J. M., GUTMAN A. B. Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione). Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):884–887. doi: 10.3181/00379727-86-21263. [DOI] [PubMed] [Google Scholar]
  2. BURNS J. J., ROSE R. K., CHENKIN T., GOLDMAN A., SCHULERT A., BRODIE B. B. The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther. 1953 Nov;109(3):346–357. [PubMed] [Google Scholar]
  3. BURNS J. J., ROSE R. K., GOODWIN S., REICHENTHAL J., HORNING E. C., BRODIE B. B. The metabolic fate of phenylbutazone (butazolidin) in man. J Pharmacol Exp Ther. 1955 Apr;113(4):481–489. [PubMed] [Google Scholar]
  4. GUTMAN A. B., YU T. F. Current principles of management in gout. Am J Med. 1952 Dec;13(6):744–759. doi: 10.1016/0002-9343(52)90374-4. [DOI] [PubMed] [Google Scholar]
  5. GUTMAN A. B., YU T. F., RANDOLPH V. Further observation on the uricosuric effects of probenecid (benemid) in tophaceous gout. Trans Assoc Am Physicians. 1954;67:250–260. [PubMed] [Google Scholar]
  6. KUZELL W. C., SCHAFFARZICK R. W., NAUGLER W. E., GAUDIN G., MANKLE E. A., BROWN B. Phenylbutazone (butazolidin) in gout. Am J Med. 1954 Feb;16(2):212–217. doi: 10.1016/0002-9343(54)90336-8. [DOI] [PubMed] [Google Scholar]
  7. SIROTA J. H., YU T. F., GUTMAN A. B. Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects. J Clin Invest. 1952 Jul;31(7):692–701. doi: 10.1172/JCI102651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. WYNGAARDEN J. B. The effect of phenylbutazone on uric acid metabolism in two normal subjects. J Clin Invest. 1955 Feb;34(2):256–262. doi: 10.1172/JCI103078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. YU T. F., GUTMAN A. B. Paradoxical retention of uric acid by uricosuric drugs in low dosage. Proc Soc Exp Biol Med. 1955 Nov;90(2):542–547. doi: 10.3181/00379727-90-22094. [DOI] [PubMed] [Google Scholar]
  10. YU T. F., GUTMAN A. B. Ultrafiltrability of plasma urate in man. Proc Soc Exp Biol Med. 1953 Oct;84(1):21–24. doi: 10.3181/00379727-84-20528. [DOI] [PubMed] [Google Scholar]
  11. YU T. F., SIROTA J. H., GUTMAN A. B. Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects. J Clin Invest. 1953 Nov;32(11):1121–1132. doi: 10.1172/JCI102836. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES